Today: 9 November 2025
Subscribe
Bristol‑Myers Squibb (BMY) today: €5B euro‑notes closing, $239M Celgene suit settlement, BioNTech cash flows lift guidance — what to watch on November 9, 2025
 ·  ·  ·  ·  ·  · 

Bristol‑Myers Squibb (BMY) today: €5B euro‑notes closing, $239M Celgene suit settlement, BioNTech cash flows lift guidance — what to watch on November 9, 2025

by
9 November 2025
  • Financing wraps up: BMS priced €5 billion of senior unsecured notes in five tranches; closing is expected Monday, Nov. 10. Proceeds will help fund a multi‑tranche debt tender offer that runs to Dec. 3 (early tender Nov. 17). [1]
  • Legal overhang addressed: A $239 million settlement of a long‑running class action tied to legacy Celgene disclosures was filed Nov. 5; it requires court approval. [2]
  • Partner cash already flowing:BioNTech lifted its 2025 revenue guidance after receiving initial payments from the new BMS immuno‑oncology alliance. [3]
  • Data weekend for Camzyos: At AHA Scientific Sessions (Nov. 7–10), BMS is presenting long‑term and real‑world data for Camzyos (mavacamten) in obstructive HCM. [4]
  • Competitive & generic currents: A fresh generic approval for dasatinib (Sprycel) landed Nov. 7, and a startup raised funding to challenge Camzyos in HCM. [5]

Financing & balance sheet: euro notes + tender offer

Bristol‑Myers Squibb priced €5 billion in senior unsecured notes across five tranches — €750M 2030 (2.973%), €1.15B 2033 (3.363%), €1.15B 2038 (3.857%), €750M 2045 (4.289%), and €1.2B 2055 (4.581%) — with closing anticipated Nov. 10, 2025. The notes are guaranteed by Bristol‑Myers Squibb Company. [6]

Proceeds, plus about $3B in cash, are earmarked to fund BMS’s cash tender offers for multiple outstanding dollar notes. The offers expire Dec. 3, 2025 (early tender Nov. 17), with maximum aggregate purchase prices of $4B (Pool 1) and $3B (Pool 2) excluding accrued coupons. [7]

Why it matters: With near‑term maturities and higher‑coupon legacy debt, the pair of transactions gives BMS flexibility to reprofile liabilities while it invests behind late‑stage assets and partnerships.

Litigation: Celgene class action settlement filed

On Nov. 5, BMS agreed to a $239 million settlement resolving claims that Celgene misled investors about prospects for Otezla and ozanimod (Zeposia) ahead of BMS’s 2019 acquisition. After fees, about $159.3 million could go to the class, pending court approval. BMS denied wrongdoing; the settlement removes a legal distraction. [8]

Pipelines & data catalysts: cardio this weekend, cell therapy next

  • Camzyos at AHA 2025 (Nov. 7–10): BMS is showcasing an extension study approaching 4 years and multiple real‑world analyses (including U.S. REMS data) in obstructive HCM, plus updates from the milvexian collaboration with J&J in thrombosis. Today (Nov. 9) sits in the middle of the meeting; additional Camzyos‑related presentations run through Monday, Nov. 10. [9]
  • Breyanzi (liso‑cel) — upcoming FDA decision: The sBLA in marginal zone lymphoma is under Priority Review with an action date of Dec. 5, 2025, a near‑term regulatory catalyst. [10]
  • Sprycel (dasatinib) pressure: The FDA approved generic dasatinib tablets (multiple strengths) on Nov. 7, adding to competitive intensity in CML/ALL and underscoring the importance of BMS’s “new product” cohort offsetting LOE headwinds. [11]

Partner ecosystem: BioNTech payments arrive; new solid‑tumor experiment

  • BioNTech collaboration: BioNTech raised 2025 revenue guidance to €2.6–€2.8B after receiving initial payments from BMS tied to their bispecific PD‑L1/VEGF program (pumitamig/BNT327), with more studies slated in 2026. This follows BMS’s commitment of up to $11.1B in total economics earlier this year. [12]
  • Dispatch Bio clinical‑supply deal: BMS will supply ide‑cel (Abecma) for Dispatch Bio’s planned Phase 1 U.S. study in solid tumors starting 2026 — a first‑of‑its‑kind clinical‑supply pact using an autologous CAR‑T in combination with a tumor‑targeting viral approach. [13]

Earnings context: Q3 scorecard sets the stage

Just ahead of this week’s financing, BMS beat Q3 revenue and EPS expectations, helped by Opdivo (including initial subcutaneous uptake) and Eliquis, while the “growth portfolio” offset steep Revlimid erosion. Headline figures: Revenue $12.22B (vs. $11.8B est.), adj. EPS $1.63; Opdivo $2.53B (+$67M from SC launch), Eliquis $3.75B. [14]

Competitive notes to watch

  • Hypertrophic cardiomyopathy:Braveheart Bio raised $185M (Nov. 5) to advance an HCM therapy licensed from Hengrui, aiming to challenge Camzyos — a reminder that Camzyos’s lead will face follow‑on entrants. [15]

Dates & deadlines (all in 2025)

  • AHA Scientific Sessions: Nov. 7–10 (Camzyos & milvexian data). [16]
  • €5B notes closing:Nov. 10 (expected). [17]
  • Debt tender offers: Early tender Nov. 17; final expiration Dec. 3. [18]
  • FDA action date — Breyanzi (MZL):Dec. 5. [19]

Bottom line

On November 9, 2025, Bristol‑Myers Squibb sits at the intersection of capital structure cleanup (euro notes + tender), pipeline proof points (Camzyos at AHA; Breyanzi PDUFA next), and partner‑powered momentum (BioNTech payments starting to hit). Legal risk is reduced via the Celgene settlement filing, while generic and competitive pressures reinforce why BMS is leaning into late‑stage assets and alliances. Near‑term investor focus: notes closing Monday, tender early‑tender participation, and Dec. 5 FDA outcome for Breyanzi. [20]

This article is for information purposes only and is not investment advice.

This $46 Stock Could Hit $70 in 2025! (Undervalued Pharma Giant)
Watch this video on YouTube.

References

1. news.bms.com, 2. www.reuters.com, 3. www.reuters.com, 4. news.bms.com, 5. www.onclive.com, 6. news.bms.com, 7. news.bms.com, 8. www.reuters.com, 9. news.bms.com, 10. www.pharmexec.com, 11. www.onclive.com, 12. www.reuters.com, 13. www.businesswire.com, 14. www.reuters.com, 15. www.biopharmadive.com, 16. news.bms.com, 17. news.bms.com, 18. news.bms.com, 19. www.pharmexec.com, 20. news.bms.com

Tags:

Mateusz Kaczmarek Latest posts

A technology and finance expert writing for TS2.tech. He analyzes developments in satellites, telecommunications, and artificial intelligence, with a focus on their impact on global markets. Author of industry reports and market commentary, often cited in tech and business media. Passionate about innovation and the digital economy.

  1. ARCC Stock Today: Ares Capital’s 9.5% Dividend, Q3 Record NAV, and Fresh Insider Buying (Nov. 9, 2025)
  2. Bristol‑Myers Squibb (BMY) today: €5B euro‑notes closing, $239M Celgene suit settlement, BioNTech cash flows lift guidance — what to watch on November 9, 2025
  3. Viking Therapeutics (VKTX) Today — Nov 9, 2025: New Institutional Buying, Fresh Technical Levels, and Key Catalysts Ahead
  4. HIVE Digital Technologies (NASDAQ: HIVE) news today — Nov. 9, 2025: Earnings date locked, 23 EH/s milestone, and AI data‑center expansion

Stock Market Today

  • Fed Dissent: Miran Pushes for 50bp Cut as Markets Watch | Interview Recap
    November 9, 2025, 3:54 PM EST. Fed Governor Stephen Miran dissented at the October meeting, arguing that delaying a larger rate cut risks the economy. He backed a 50bp cut rather than the Fed's 25bp move, warning that a smaller path could leave inflation and growth unsupported. In a sit-down with Yahoo Finance's Jennifer Schonberger, Miran details his concerns about delaying relief and the potential market impact. The interview sheds light on how this dissent could influence traders watching markets and the latest Market Catalysts action. For those seeking deeper insight, watch the full Yahoo Finance interview to gauge what the Fed's stance could mean for stocks, bonds, and the broader investment backdrop.
  • Pelosi's $130M Stock Profits: Report Details Huge Market Gains Across Her Congressional Career
    November 9, 2025, 3:22 PM EST. New reporting suggests former House Speaker Nancy Pelosi and her husband, Paul Pelosi, amassed more than $130 million in stock profits over Nancy Pelosi's four-decade congressional tenure. Citing the New York Post, the couple allegedly achieved a staggering 16,930% return, far outpacing the Dow's growth during the same period. The Pelosis reportedly held securities from before her 1987 entry to Congress, including Citibank, with their portfolio swelling from an estimated $610k-$785k to about $133.7 million. The report comes as Pelosi, 85, announced she will not seek reelection after her term ends in 2027. The figures add fuel to ongoing discussions about stock holdings by lawmakers and financial disclosure transparency.
  • AllianceBernstein Holding (AB) Valuation in Focus After Share Price Momentum
    November 9, 2025, 3:08 PM EST. AllianceBernstein Holding (AB) has edged higher this year, with a 16.5% TSR over the past twelve months and a recent momentum backdrop. The stock trades at a P/E of 11x, well below the industry average 24.4x and a peer average 34.7x, hinting at potential undervaluation of its earnings power. The SWS model's take shows a fair value around $46.51 per share, roughly 15.8% above the current price. If results beat expectations or sector sentiment improves, the valuation gap could narrow. However, concerns on revenue volatility and modest net income growth persist. The key question remains whether the market has already priced in future growth or if further upside awaits.
  • HMM.A:CA Stock Analysis and AI Signals - Hammond Manufacturing (CA)
    November 9, 2025, 3:06 PM EST. Updated AI-generated signals and ratings for HMM.A:CA (Hammond Manufacturing Company Limited Class A Subordinate Voting Shares) are highlighted here for November 9. The plan leans toward a long-term approach with a Buy near 10.87 and a stop loss @ 10.82; there are no short plans offered at this time. The page notes AI Generated Signals and links to an updated signals analysis. Ratings cover the near, mid, and long terms: Near - Strong, Mid - Strong, Long - Neutral. Investors are guided by these AI-driven signals when evaluating entries on HMM.A:CA.
  • BKV Valuation Review: 1-Month Rally, P/S at 2.8x, DCF Shows Upside
    November 9, 2025, 2:48 PM EST. BKV extended its recent uptrend, rising ~2.5% in the latest session on momentum built over the last month. The stock has delivered a 1-month return of 24% and a total shareholder return of 30% in the past year, reflecting improving sentiment around growth. At $25.39 per share, the price-to-sales (P/S) ratio sits at 2.8x, below the peer group average of 3.2x but above the broad sector average of 1.5x, suggesting investors expect growth but see execution risks. If the market revisits a fair P/S around 2.0x, upside could temper. A contrasting view comes from a DCF-based fair value of $114.96 per share, implying substantial upside but relying on continued revenue momentum and profitability improvements. Net losses persist, so risk remains if growth slows.
Viking Therapeutics (VKTX) Today — Nov 9, 2025: New Institutional Buying, Fresh Technical Levels, and Key Catalysts Ahead
Previous Story

Viking Therapeutics (VKTX) Today — Nov 9, 2025: New Institutional Buying, Fresh Technical Levels, and Key Catalysts Ahead

ARCC Stock Today: Ares Capital’s 9.5% Dividend, Q3 Record NAV, and Fresh Insider Buying (Nov. 9, 2025)
Next Story

ARCC Stock Today: Ares Capital’s 9.5% Dividend, Q3 Record NAV, and Fresh Insider Buying (Nov. 9, 2025)

Related Articles

Go toTop